Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer

Guetz, G. Des; Uzzan, Bernard; Morère, Jean‐François; Perret, G; Nicolas, Patrick

doi:10.1002/14651858.cd007046.pub2

Cited by 45 publications

(41 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current recommendations are for patients with high-risk stage Ⅱ and stage Ⅲ CRC to receive 6 mo of adjuvant chemotherapy after primary surgical resection, and for patients with low-risk stage Ⅱ CRC to be considered for adjuvant chemotherapy, enrolled in a clinical trial or observed without adjuvant therapy [77,79] . The specific chemotherapeutic regimens have been reviewed recently in detail [77,80] .…”

Section: Adjuvant Therapy and Surveillancementioning

confidence: 99%

Genomic era diagnosis and management of hereditary and sporadic colon cancer

Snyder

2014

WJCO

View full text Add to dashboard Cite

The morbidity and mortality attributable to heritable and sporadic carcinomas of the colon are substantial and affect children and adults alike. Despite current colonoscopy screening recommendations colorectal adenocarcinoma (CRC) still accounts for almost 140000 cancer cases yearly. Familial adenomatous polyposis (FAP) is a colon cancer predisposition due to alterations in the adenomatous polyposis coli gene, which is mutated in most CRC. Since the beginning of the genomic era next-generation sequencing analyses of CRC continue to improve our understanding of the genetics of tumorigenesis and promise to expand our ability to identify and treat this disease. Advances in genome sequence analysis have facilitated the molecular diagnosis of individuals with FAP, which enables initiation of appropriate monitoring and timely intervention. Genome sequencing also has potential clinical impact for individuals with sporadic forms of CRC, providing means for molecular diagnosis of CRC tumor type, data guiding selection of tumor targeted therapies, and pharmacogenomic profiles specifying patient specific drug tolerances. There is even a potential role for genomic sequencing in surveillance for recurrence, and early detection, of CRC. We review strategies for diagnostic assessment and management of FAP and sporadic CRC in the current genomic era, with emphasis on the current, and potential for future, impact of genome sequencing on the clinical care of these conditions. © 2014 Baishideng Publishing Group Inc. All rights reserved.Key words: Colorectal adenocarcinoma; Familial adenomatous polyposis; Genome sequencing; Personalized medicine; Cancer genomics; Pharmacogenomics; Genomic medicine Core tip: The era of genomic sequencing is beginning to make significant impact on the diagnosis and management of sporadic and inherited colorectal adenocarcinoma (CRC) such as familial adenomatous polyposis. This review will discuss the current guidelines for diagnosis and management of CRC and how genomic sequencing is enabling earlier definitive diagnosis with associated intensive surveillance and preventative interventions, molecular tumor characterization directing tumor specific therapy, germline patient genome analysis which informs individual drug tolerance and efficacy, and is evolving to develop post-treatment surveillance, with the potential to ultimately decrease the current prevalence and mortality of CRC, sporadic and hereditary.Esplin ED, Snyder MP. Genomic era diagnosis and management of hereditary and sporadic colon cancer. World J Clin Oncol 2014; 5(5): 1036-1047 Available from: URL: http://www. wjgnet.com/2218-4333/full/v5/i5/1036.htm DOI: http://dx.doi. org/10.5306/wjco.v5.i5.1036 INTRODUCTIONThe annual incidence in the United States of colorectal adenocarcinoma (CRC) is almost 140000 [1] . The morbidi- ty and mortality attributable to heritable and sporadic carcinomas of the colon are substantial and affect children and adults alike, with CRC being the third highest cause of cancer mortality among men and wom...

show abstract

Section: Adjuvant Therapy and Surveillancementioning

confidence: 99%

Genomic era diagnosis and management of hereditary and sporadic colon cancer

Snyder

2014

WJCO

View full text Add to dashboard Cite

show abstract

“…Mediante colectomía y resección en bloque de ganglios locorregionales, en paciente sin metástasis, una cirugía completa puede ser curativa 6 . Los pacientes con enfermedad etapa clínica I no requieren terapia adyuvante 7 8 . Del 60% de los pacientes con CCR que presentarán metástasis, un 80% tienen enfermedad hepática irresecable; la enfermedad hepática es la causa más frecuente de muerte en estos pacientes.…”

Section: Introductionunclassified

Angiogénesis y hemostasia en cáncer colorrectal

Agredano-Pérez¹,

Mariscal-Ramírez²,

Ronquillo-Carreón³

et al. 2022

GAMO

View full text Add to dashboard Cite

Resumen Mundialmente, el cáncer colorrectal representa la tercera causa de muerte en hombres y la segunda causa de muerte en mujeres, con cerca de 1.2 millones de casos nuevos diagnosticados y 600,000 muertes estimadas. Una proporción importante de pacientes son diagnosticados con enfermedad metastásica al momento del diagnóstico. La neoangiogénesis es la formación de nuevos vasos sanguíneos a partir de los existentes, los cuales juegan un papel importante en la progresión y crecimiento tumoral. Se han identificado factores relacionados con el crecimiento endotelial, entre ellos el factor de crecimiento endotelial vascular. Diversos estudios han demostrado la participación en el desarrollo angiogénico tumoral de la activación de los sistemas de la coagulación y fibrinólisis. Algunos de estos factores son el factor von Willebrand, el fibrinógeno, el activador del plasminógeno de tipo I, su inhibidor y su receptor, además del dímero D y las plaquetas. Se considera que las concentraciones séricas de estas proteínas son factores predictivos de respuesta al tratamiento, progresión de la enfermedad y superviviencia. La interacción entre las células tumorales, la angiogénesis y la activación de la coagulación es una retroalimentación positiva. Las estrategias que interfieran en esta relación pueden prevenir o tratar el cáncer, como el uso de quimioterapia en combinación con nuevos agentes específicos de diana. Además, el papel de los anticoagulantes o antiplaquetarios en el tratamiento del cán-cer aún no se ha determinado. (creativecommons.org/licenses/by-nc-nd/4.0/). Abstract Worldwide, colorectal cancer is the third cause of death in men and the second leading cause of death in women, with about 1.2 million new cases diagnosed and 600,000 estimated deaths. A significant proportion of patients are diagnosed with metastatic disease at diagnosis. Angiogenesis is the formation of new blood vessels from existing ones, which play an important role in tumor growth and progression. Factors related to endothelial growth, including vascular endothelial growth factor, have been identified. Several studies have shown the PALABRAS CLAVEAngiogénesis; Cáncer colorrectal; Estado protrombótico; Pronóstico; Trombosis; Factor de crecimiento endotelial vascular (VEGF)

show abstract

“…For patients with clinical Stage III disease, 6-month chemotherapy is recommended, and they can receive FOL-FOX or CapeOx; FLOX, or capecitabine monotherapy or 5-fluorouracyl/leucovorin in those in whom oxaliplatin is contraindicated 8 . Out of 60% of CRC patients that will develop metastasis, 80% will develop unresectable liver disease, with liver disease being the most common cause of death in these patients.…”

Section: Introductionmentioning

confidence: 99%

Angiogenesis and hemostasis in colorectal cancer

Agredano-Pérez¹,

Mariscal-Ramírez²,

Ronquillo-Carreón³

et al. 2022

GAMO

View full text Add to dashboard Cite

Worldwide, colorectal cancer is the third cause of death in men and the second cause of death in women, with nearly 1.2 million newly-diagnosed cases and 600,000 estimated deaths. A significant proportion of patients have metastatic disease at diagnosis. Neoangiogenesis is the formation of new blood vessels from those already existing, which play an important role in tumor growth and progression. Factors related to endothelial growth have been identified including vascular endothelial growth factor. Different studies have demonstrated coagulation and fibrinolysis systems activation participation in tumor angiogenic development. Some of these factors are Von Willebrand factor, fibrinogen, type I plasminogen activator inhibitor and receptor, in addition to D-dimer and platelets. Serum concentrations of these proteins are considered to be predictors of treatment response, disease progression and survival. Interaction between tumor cells, angiogenesis and coagulation activation is a positive feedback, and strategies interfering in this relationship, such as the use of chemotherapy in combination with new specifically targeted agents, can prevent or treat cancer. In addition, the role of anticoagulant or antiplatelet agents in the treatment of cancer has not yet been determined. (creativecommons.org/licenses/by-nc-nd/4.0/).

show abstract

Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer

Cited by 45 publications

References 10 publications

Genomic era diagnosis and management of hereditary and sporadic colon cancer

Genomic era diagnosis and management of hereditary and sporadic colon cancer

Angiogénesis y hemostasia en cáncer colorrectal

Angiogenesis and hemostasis in colorectal cancer

Contact Info

Product

Resources

About